What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus

Details

• Alternative Title:
  Obstet Gynecol
• Personal Author:
  Debessai, Haben ; Jones, Jefferson M. ; Meaney-Delman, Dana ; Rasmussen, Sonja A.
• Description:
  Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections in neonates, infants, and children worldwide. The virus is estimated to infect 97% of this population in the United States by the age of 2 years, leading to hospitalization for severe lower respiratory tract disease in 2-3% of infants younger than age 6 months. Two preventive options, prenatal administration of a maternal vaccine and administration of a long-acting monoclonal antibody to the infant, are now available for the prevention of RSV-associated lower respiratory tract infection in infants in the United States. The U.S. Food and Drug Administration (FDA) has approved and the Centers for Disease Control and Prevention (CDC) has recommended a new maternal vaccination, RSVPreF, to be administered between 32 0/7 and 36 6/7 weeks of gestation to reduce the risk of RSV-associated lower respiratory tract infection in infants in the first 6 months of life. The monoclonal antibody nirsevimab was approved by the FDA and recommended by the CDC for prevention of RSV-associated lower respiratory tract infection in infants younger than age 8 months who are born during or entering their first RSV season and for infants and children aged 8-19 months who are at high risk for RSV-associated lower respiratory tract infection and entering their second RSV season. Either maternal vaccination during pregnancy or monoclonal antibody administration to the infant is recommended to prevent RSV-associated lower respiratory tract infection among infants, but both are not needed for most infants. Given that the availability of these products may vary as these recommendations are implemented, it is important that obstetricians and other prenatal practitioners have the information they need to counsel their pregnant patients about both options. We review the safety and efficacy of these products, current recommendations for their use, and relative advantages and disadvantages of both newly approved options for the prevention of RSV-associated lower respiratory tract infection in infants to assist obstetricians and other prenatal practitioners in their counseling of pregnant patients.
• Subjects:
  Antibodies, Monoclonal Antiviral Agents Child Female Humans Infant Infant, Newborn Obstetricians Pregnancy Respiratory Syncytial Virus, Human Respiratory Syncytial Virus Infections Respiratory Tract Infections United States

  More +
• Source:
  Obstet Gynecol. 143(3):e54-e62
• Pubmed ID:
  38061043
• Pubmed Central ID:
  PMC11164561
• Document Type:
  Journal Article
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Volume:
  143
• Issue:
  3
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:94d00c98adb5a48dcbe8f3dc4f61ec2547c13d868ec8f372dfc3777a3aa46d47
• Download URL:
  https://stacks.cdc.gov/view/cdc/157944/cdc_157944_DS1.pdf
• File Type:
  [PDF - 468.90 KB ]